News and Trends 1 Nov 2022 Pancreatic cancer could be diagnosed years earlier Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research from the U.K. shows. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates. In the largest study of its kind, researchers […] November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 First patient enrolled and dosed on expansion phase of cancer treatment trial The first patient in an expansion phase of a trial looking at cancer drug Modi-1 has been enrolled and dosed. Scancell Holdings plc, the developer of immunotherapies for the treatment of cancer and infectious disease made the announcement today (October 31). The expansion phase is part of the monotherapy arms of the phase 1 clinical […] October 31, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets U.K. biopharma company PhoreMost Ltd. has entered into a multi-target collaboration with Arvinas, a company active in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and commercial milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. […] October 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Reprogramming immune cells can fight melanoma A new way of reprogramming immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard-to-treat skin cancer, melanoma. The University of Bristol, in the U.K. led the discovery, which has been published in Advanced Science. It demonstrates a new way to clear early stage pre-cancerous and even […] October 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 28 Oct 2022 ‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say A whole new level of control of cancer gene activity within tumors, has been described by researchers as ‘dark matter’. It was recently discovered and published in two major studies at the same time in Nature that cancers can evolve to become more aggressive without relying on DNA mutations. Testing cancers for just the DNA […] October 28, 2022 - 6 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2022Beyond Biotech podcast 20: BioWin, eTherapeutics, CMT Research Foundation This week, we have three interviews, and four guests. We chatted with Keith Fargo, chief scientific officer at the CMT Research Foundation; François Colery, head of the Talent Now initiative and Sylvie Ponchaut, managing director, from BioWin; and e-therapeutics’ CEO, Ali Mortazavi. We also have our weekly contribution from global commercial real estate services company […] October 28, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Scancell signs agreement with Genmab Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer and infectious disease, has signed a licensing agreement with Genmab, an international biotechnology company, to develop and commercialize a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products. Genmab has been granted the exclusive right to develop and commercialize the Scancell antibody […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 New UK spinout VacV Biotherapeutics emerges from stealth to work on cancer immunotherapies VacV Biotherapeutics, a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth mode today to advance its pipeline of pre-clinical assets with best-in-class potential, towards the clinic. VacV Biotherapeutics has spun out of Barts Cancer Institute and Queen Mary University of London following 20 years of research by immunotherapy experts Yaohe Wang, Nicholas Lemoine, […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 25 Oct 2022 Precision medicine research must lose its Eurocentricity Precision medicine research relies on genetic testing at scale, but how do we reach more diverse patient populations and collect nationally representative samples? Patrick Short, CEO and co-founder of Sano Genetics, and Natasha Ratcliffe, director of community engagement and partnerships at Couch Health, explain how Eurocentricity is holding back genetics, and what can be done. […] October 25, 2022 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 24 Oct 2022 Hiding in plain sight: how to solve bioscience’s software problem Guy Levy-Yurista, CEO of the experiment platform developer Synthace, gives his take on what’s missing in increasingly software-dependent life sciences labs: a holistic mindset for improving experimental methods. There’s a major problem holding back progress in biotech, and more widely in the life sciences. It’s not an obvious one, but based on the conversations I […] October 24, 2022 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 20 Oct 2022 Opportunities and challenges for cell and gene therapy investments Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […] October 20, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 AbbVie acquires LifeArc portfolio company DJS Antibodies AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email